Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet.
Rock, Gail 1; Anderson, David 2; Clark, William 3; Leblond, Pierre 4; Palmer, Douglas 5; Sternbach, Marion 6; Sutton, David 7; Wells, George 8; members of the Canadian Apheresis Group and members of the Canadian Association of Apheresis Nurses *
[Article] British Journal of Haematology. 129(1):79-86, April 2005.

(Format: HTML, PDF)

Summary: A randomized prospective trial compared cryosupernatant plasma (CSP) to fresh frozen plasma (FFP) for treatment of thrombotic thrombocytopenic purpura (TTP). A total of 236 patients were required: 28 patients were treated with CSP and 24 with FFP within 30 months. There were no differences in survival at 1 month. By day 9, 17 of 26 patients with CSP and 18 of 24 with FFP had a platelet count >100 x 109/l. At entry, von Willebrand factor (VWF) multimers were normal in all patients (range 1[middle dot]1-3[middle dot]95 IU/ml). ADAMTS-13 levels showed large variations ranging from 10% to 100% activity. At entry, no individual had <5% VWF cleaving protease. By day 9 (end of cycle), 89% (FFP) and 67% (CSP) had levels >50% of the controls. At 6 months some patients showed inhibitors to the enzyme in spite of adequate or normal platelet counts. The data from this study do not show an apparent advantage to the use of CSP in TTP. A large number of patients will be required to determine appropriate replacement therapy. We were not able to find a statistically significant relationship between the low level of protease activity at presentation of TTP and response.

Copyright (C) 2005 Blackwell Publishing Ltd.